Cardiac Excitation and Contraction: Atrial fibrillation and electrophysiology in transgenic mice with cardiac-restricted overexpression of FKBP12
暂无分享,去创建一个
M. Fishbein | M. Rubart | Peng-Sheng Chen | W. Shou | Shien‐Fong Lin | Hanying Chen | P. Chang | M. Maruyama | Deyong Xiao | Jijia Liu | M. Homsi | Baiyan Li | Zhenwei Pan
[1] K. Tsaneva-Atanasova,et al. FKBP12 Activates the Cardiac Ryanodine Receptor Ca2+-Release Channel and Is Antagonised by FKBP12.6 , 2012, PloS one.
[2] D. Roden,et al. Striking In Vivo Phenotype of a Disease-Associated Human SCN5A Mutation Producing Minimal Changes in Vitro , 2011, Circulation.
[3] S. Johnston,et al. Estimation of Total Incremental Health Care Costs in Patients With Atrial Fibrillation in the United States , 2011, Circulation. Cardiovascular quality and outcomes.
[4] M. Fishbein,et al. FKBP12 Is a Critical Regulator of the Heart Rhythm and the Cardiac Voltage-Gated Sodium Current in Mice , 2011, Circulation research.
[5] Ning Wang,et al. MicroRNA-328 Contributes to Adverse Electrical Remodeling in Atrial Fibrillation , 2010, Circulation.
[6] S. Tsang,et al. Differential gene expressions in atrial and ventricular myocytes: insights into the road of applying embryonic stem cell-derived cardiomyocytes for future therapies. , 2010, American journal of physiology. Cell physiology.
[7] Stefan Wagner,et al. Altered Na(+) currents in atrial fibrillation effects of ranolazine on arrhythmias and contractility in human atrial myocardium. , 2010, Journal of the American College of Cardiology.
[8] S. Connolly,et al. Prevention of Atrial Fibrillation: Report From a National Heart, Lung, and Blood Institute Workshop , 2009, Circulation.
[9] D. Roden,et al. Cardiac Sodium Channel (SCN5A) Variants Associated with Atrial Fibrillation , 2008, Circulation.
[10] A. Wilde,et al. Cardiac sodium channel overlap syndromes: different faces of SCN5A mutations. , 2008, Trends in cardiovascular medicine.
[11] D. Franco,et al. Tissue distribution and subcellular localization of the cardiac sodium channel during mouse heart development. , 2008, Cardiovascular research.
[12] D. Tester,et al. A novel C-terminal truncation SCN5A mutation from a patient with sick sinus syndrome, conduction disorder and ventricular tachycardia. , 2007, Cardiovascular research.
[13] Andrew C. Zygmunt,et al. Atrium-Selective Sodium Channel Block as a Strategy for Suppression of Atrial Fibrillation: Differences in Sodium Channel Inactivation Between Atria and Ventricles and the Role of Ranolazine , 2007, Circulation.
[14] T. Olson,et al. A Common Polymorphism in SCN5A is Associated with Lone Atrial Fibrillation , 2007, Clinical pharmacology and therapeutics.
[15] P. Carmeliet,et al. Overlap Syndrome of Cardiac Sodium Channel Disease in Mice Carrying the Equivalent Mutation of Human SCN5A-1795insD , 2006, Circulation.
[16] A. Hofman,et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. , 2006, European heart journal.
[17] J. D. de Bakker,et al. Impaired Impulse Propagation in Scn5a-Knockout Mice: Combined Contribution of Excitability, Connexin Expression, and Tissue Architecture in Relation to Aging , 2005, Circulation.
[18] D. Gros,et al. Mouse Model of SCN5A-Linked Hereditary Lenègre’s Disease: Age-Related Conduction Slowing and Myocardial Fibrosis , 2005, Circulation.
[19] Y. Rudy,et al. Basic mechanisms of cardiac impulse propagation and associated arrhythmias. , 2004, Physiological reviews.
[20] C. Lau,et al. Heterogeneity of sodium current in atrial vs epicardial ventricular myocytes of adult guinea pig hearts. , 2002, Journal of molecular and cellular cardiology.
[21] M. Rosen,et al. Density and function of inward currents in right atrial cells from chronically fibrillating canine atria. , 2002, Cardiovascular research.
[22] A. A. Armoundas,et al. Electrical and structural remodeling of the failing ventricle. , 2001, Pharmacology & therapeutics.
[23] C. Tracy,et al. QT prolongation and near fatal cardiac arrhythmia after intravenous tacrolimus administration: a case report. , 1998, Transplantation.
[24] S. Marx,et al. Coupled gating between individual skeletal muscle Ca2+ release channels (ryanodine receptors) , 1998, Science.
[25] M. Matzuk,et al. Cardiac defects and altered ryanodine receptor function in mice lacking FKBP12 , 1998, Nature.
[26] P. Baliga,et al. Bradycardia Associated with Intravenous Administration of Tacrolimus in a Liver Transplant Recipient , 1997, Pharmacotherapy.
[27] S. Mizuno,et al. Sinus arrest during tacrolimus (FK506) and digitalis treatment in a bone marrow transplant recipient. , 1997, Transplantation.
[28] E. Lakatta,et al. The immunophilin FK506‐binding protein modulates Ca2+ release channel closure in rat heart. , 1997, The Journal of physiology.
[29] D. Bers,et al. Effects of FK-506 on contraction and Ca2+ transients in rat cardiac myocytes. , 1996, Circulation research.
[30] P. Donahoe,et al. The Immunophilin FKBP12 Functions as a Common Inhibitor of the TGFβ Family Type I Receptors , 1996, Cell.
[31] J. Ruskin,et al. Cardiac sodium channel mutation in atrial fibrillation. , 2008, Heart rhythm.